CervoMed Inc. (CRVO) FDA Lifts Exposure Cap; New Tablet Supports 100 mg BID
CervoMed reported a new 50 mg neflamapimod tablet with BID-friendly PK and said the FDA removed a prior plasma exposure limit, enabling plans to advance a 100 mg twice-daily regimen in future trials.Material DetailsContext by AI AnalystThis is an R&D and regulatory de-risking step for neflamapimod…